Beyond the Tumor Mass: From Initiating Clones to Overt Isocitrate Dehydrogenase-Mutant Gliomas

Area of Science:

• Neuro-oncology
• Molecular Biology
• Cancer Genetics

Background:

• Isocitrate dehydrogenase (IDH)-mutant gliomas are primary malignant brain tumors characterized by IDH1/2 gene mutations.
• These mutations are early events, but IDH1 mutant cells can exist in peritumoral cortex, challenging a gene-centric view of gliomagenesis.

Purpose of the Study:

• To review emerging data supporting a multistep, context-dependent model of gliomagenesis.
• To discuss the distinction between the "cell-of-mutation" and "cell-of-origin."
• To explore how temporal stratification of tumor evolution can inform therapeutic strategies.

Main Methods:

• Literature review of emerging data on IDH-mutant gliomas.
• Conceptual analysis of gliomagenesis models.
• Discussion of therapeutic implications.

Main Results:

• Emerging data support a multistep model where mutant IDH establishes an epigenetically altered state, followed by genetic alterations and lineage constraints.
• Cells harboring the founding mutation can persist beyond the tumor mass with nonmalignant features.
• A conceptual distinction between "cell-of-mutation" and "cell-of-origin" is proposed.

Conclusions:

• Glioma development is a multistep process influenced by epigenetic changes, genetic alterations, and cellular context.
• Understanding the temporal evolution of tumor clones, including those outside the overt tumor mass, is crucial.
• Stage-specific therapeutic strategies may be informed by the transition from initiating clones to overt tumors.